Insulin glargine
Insulin glargine (Lantus, Basaglar, Semglee): approval history, the first interchangeable biosimilar, hypoglycemia warnings and WADA status.
FDA-approved, prescription only · Evidence grade A · Reviewed
- FDA-approvedDiabetesLantus, Basaglar, Semglee and others
WADA prohibits insulins at all times under S4 (hormone and metabolic modulators).
Drug-tested athletes can look up any substance on Global DRO, run by national anti-doping agencies. Supplements can contain banned substances that are not on the label. Drawline does not suggest when to train or inject.
Insulin glargine (Lantus, Basaglar, Semglee, Toujeo, Rezvoglar, long-acting insulin). Long-acting insulin analog.
AFDA-approved, prescription only. Evidence grade A: approved, large human trials.
What is Insulin glargine?
Insulin glargine is a lab-made, long-acting form of insulin that lowers blood sugar steadily over about a day. It is injected under the skin.
Is Insulin glargine FDA-approved?
FDA first approved Lantus on April 20, 2000, to improve blood sugar control in diabetes. Basaglar followed on December 16, 2015, through an abbreviated pathway. Insulins became licensed biologics on March 23, 2020, and on July 28, 2021, FDA approved Semglee (insulin glargine-yfgn) as the first interchangeable biosimilar insulin, which pharmacists may substitute for Lantus where state law allows. It is not a controlled substance.
What does the evidence show for Insulin glargine?
Large randomized trials and decades of use in type 1 and type 2 diabetes support its approved use. There is no good evidence for use by people without diabetes.
What are the known risks of Insulin glargine?
Low blood sugar is the most common side effect and can cause seizures, loss of consciousness or death, especially in people without diabetes or after dose mix-ups. Labels warn never to share a pen, cartridge or syringe between people, even with a new needle, because of the risk of blood-borne infection. Insulin can also cause low potassium, which can be life-threatening. WADA prohibits insulins at all times under S4 (hormone and metabolic modulators).
How is Insulin glargine measured?
Lantus and Humalog are U-100 insulins: on a U-100 insulin syringe, each unit mark is one unit of insulin, so there is nothing to convert. Pens are pre-measured. Insulin doses come only from the prescriber.
Sources: FDA label: Lantus (insulin glargine), 2019; FDA: First interchangeable biosimilar insulin approved (Drug Information Update); FDA: Deemed to be a License provision of the BPCI Act; German Sport University Cologne: S4 hormone and metabolic modulators. This profile does not recommend any dose or use.
For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.
Keep reading
Spot a mistake or an out-of-date fact? Report an error. We check every report against the sources.